model and building block for a European shield against counterfeit pharmaceuticals a system description
|
|
- Dominick Patterson
- 8 years ago
- Views:
Transcription
1 model and building block for a European shield against counterfeit pharmaceuticals a system description
2
3 I. Introduction 4 II. Stakeholder Governance of the securpharm verification system 6 a Serialisation and labelling process is extremely complex 7 b Development, setup and running of extremely complex databases central, EU-wide model impossible 8 c Direct financing of the databases by the stakeholders 10 d Good tradition / experience with stakeholder models / self-governing models in Germany accessibility and supervision by competent authorities are a given 10 Conclusion to II 11 III. encoding of the data matrix code 12 Conclusion to III 13 IV. end to end -Verification 13 Conclusion to IV 14 V. Market and system accessibility 14 Conclusion to V 15 VI. data protection and data security 15 Conclusion to VI 16 VII. Fee model 17 Conclusion to VII 18 VIII. securpharm as blueprint for national verification systems 18 IX. Afterword 19 This system description is available in German and can be requested via info@securpharm.de
4 I. Introduction According to article 54a, section 1, of the amended anti-counterfeiting directive 2001/83/EC, prescription drugs are generally to be marked with security features that allow people to validate their authenticity and identify individual packages. The details of the properties and technical specifications of the unique identifier for the security features as well as the modalities of verification will be determined by the European Commission in delegated legal acts. According to article 2, section 2, b) of the anti-counterfeiting directive, member states will need to comply with the provisions regarding labelling and security features no later than three years after the publication of the delegated legal acts i.e. by the end of 2017, if nothing changes. The organisational, logistical and technical process of the entire drug-verification system from applying the safety features on the packaging of pharmaceuticals to checking and identifying the authenticity of the individual packages at the pharmacy is very complex. That is why in Germany the associations of market operators, namely the federal union of ABDA Federal Union of German Associations of Pharmacists (ABDA - Bundesvereinigung Deutscher Apothekerverbände), the federal association of pharmaceutical wholesalers (Bundesverband des pharmazeutischen Großhandels, PHAGRO), the federal association of pharmaceutical manufacturers (Bundesverband der Arzneimittel-Hersteller, BAH), the German pharmaceutical industry association (Bundesverband der pharmazeutischen Industrie, BPI) and the association of researching pharmaceutical companies (Verband Forschender Arzneimittelhersteller, vfa), have already agreed in mid to implement the anticounterfeiting directive and to develop and run a drug verification system using data
5 matrix codes and following the end-to-end approach. In this securpharm project, which is supported by the stakeholders, the authenticity of the drug packages marked by the pharmaceutical companies with the security features is verified online against a database of packaging details prior to being sold to the patients. Independent of this procedure, the wholesalers can initiate additional checks. Verification requests from pharmacies or wholesalers are passed on anonymously to the pharmaceutical manufacturers (MAH database) via the database of the pharmacies server, which is being developed and operated by the ABDATA pharmaceutical data service central. The MAH database has been developed and is operated by the manufacturers associations BAH, BPI and vfa as part of ACS PharmaProtect GmbH. Since January 2013, the secur- Pharm verification system is being successfully tested and constantly developed further under the real conditions of the German pharmaceutical market, i.e. without targeted deliveries of securpharm drugs to the pharmacies participating in the project. The securpharm verification system will be fully marketable by 2016 at the latest, i.e. it will be technically and organisationally sufficiently developed to verify all drugs requiring verification in Germany (depending on the configuration of the exception lists in the delegated legal acts, this will amount to 600 to 700 million packages of pharmaceuticals per year). 5
6 II. Stakeholder Governance of the securpharm verification system In Germany, the associations of market participants, i.e. the stakeholders, have agreed to implement the anti-counterfeiting directive by developing, testing and running the securpharm verification project. With regard to governance, i.e. the development, installation, management and accessibility of the data storage and retrieval system, the anti-counterfeiting directive (see article 54a paragraph 2, e) is open, meaning it does not prescribe a form of governance. Within the framework of the stakeholder workshop on 6 December 2013, the EU Commission has presented three governance options: a (national) stakeholder model, which would be surveyed by the responsible (national) authorities a central authority model at EU level a national authority model On 31 January 2014, subsequent to the workshop and as a result of the so-called impact assessment, the Commission notified the stakeholders in writing that it would establish a binding stakeholder model for the member states while taking into account the cost-effectiveness in the delegated legal acts. Quote: The repository containing the unique identifiers will be set up and managed by stakeholders. National competent authorities will be able to access and supervise the database. This means that the stakeholder verification system by securpharm complies with all terms of the anti-counterfeiting directive and the binding pan-european guidelines of the delegated legal acts. Incidentally, the following reasons speak for a verification system developed by the market operators..
7 a) Serialisation and labelling process is extremely complex Labelling packages with the security features and verifying them through the anti-counterfeiting directive is mandatory. However, the verification, and especially first of all applying the safety features on the individual drug packages, demands a considerable technical and logistical effort, which can only be made and realised by all parties involved when adhering to previously uniformly defined specifications. The pharmaceutical businesses need to generate serial numbers according to specified encoding rules provide the order data including the serial numbers for the online printing process gather the data along the packaging line specify a method of online printing undertake necessary packaging changes integrate systems and processes into the packaging procedure come to an agreement with ACS PharmaProtect over using the MAH database report the pharmaceuticals that need to be verified to the IFA set up lines of communication with the MAH database create an XML file and upload it onto the MAH database watch out for exceptions, e.g. for so-called multi-country packs or hospital packs, etc. This list of tasks alone shows how complex the serialisation and labelling process is for any pharmaceutical company. Since mid-2011, the stakeholders have jointly developed a comprehensive set of encoding rules, guidelines and specifications concerning the demands, prerequisites and procedures of the serialisation and labelling process. These have been defined and scheduled for the start of the project at the beginning of Even with support from the companies, it is difficult to nigh on impossible for the competent authorities (as a rule, the national approval agencies) to completely realise this complex process and to implement it as specified. Already for this reason alone, organising, executing, determining and supervising this colossal process should be handled by the stakeholders. 7
8 b) Development, setup and running of extremely complex databases central, EU-wide model impossible In Germany, pharmacists dispense approx. 700 million packages of prescription drugs to patients every year. And every year subject to the final list of pharmaceuticals that will require verification according to the delegated legal acts of the Commission the data of approx. 700 million packages will need to be recorded on a database for the verification process. In addition to the so-called product master data such as the name of the pharmaceutical company, drug name, dosage form etc., the packaging data which is vitally important for the verification namely the product number and serial number (securpharm also records the batch number and expiry date) need to be uploaded onto a database, saved and kept available for verification by authorised persons. Moreover, the MAH database also needs to recognise exceptions, i.e. packages that have been identified as not to be dispensed. The volume of the data that needs to be uploaded and the functionalities of this MAH database are both immense and complex. The associations of pharmaceutical producers BAH, BPI and vfa do not themselves have the necessary knowhow in the area of information technology to develop, test and run such a complex database. That is why, in August 2012, the specially founded joint subsidiary ACS PharmaProtect GmbH has commissioned a globally leading IT company to develop, test, run and host the MAH database. It is not imperative that only the market operators (can) develop, run and finance this complex database structure. However, due to the pharmaceutical companies special expertise and familiarity with the subject of processing all the data from generating, applying and uploading it down to making the verification request it is objectively necessary that the participants organise, manage, execute, and finance the whole process. These commonly defined rules and structures are market-oriented, i.e. they reflect the experiences and needs of the real pharmaceutical market. It is unlikely that a process initiated and controlled by the authorities would be quicker, cheaper and better. The process, for which the stakeholders are directly responsible, is ideally suited to implement the anti-counterfeiting directive which the securpharm project demonstrates impressively. From this, it also follows that a central EU-wide predetermined authorities model (possibly joined with the European Medicines Agency EMA) would be extremely expensive, complex and very difficult
9 to implement due to the fact that ten billion packages of pharmaceuticals are sold in Europe every year, which means a huge amount of data that needs to be processed. Moreover, up until now, the databases that are to be created by the EMA have either been implemented too late or not at all, especially in the area of pharmacovigilance this implies that experience with large, complex, central databases is not good. This is another argument for decentralised, i.e. national, database and verification systems. Experience shows that highly complex IT systems like this one need a long test and optimisation phase. The securpharm system has been up and running since January The time since then has been used to continually improve and further develop the system on the basis of the concrete experiences gained when operating it. This continuous improvement is ongoing and will remain necessary for quite some time. Within this framework, software faults have been and are being eliminated. Predominantly, however, the software is being adjusted to suit the requirements, which can only be figured out when using the programme for real. Experience has thus far shown that the greatest challenges do not arise on a technical level within the database systems: the greatest challenge is to adjust the operational procedures at the manufacturers, wholesalers and pharmacies. Making the necessary changes requires a considerable amount of time. Every new participant irrespective of whether he is on the manufacturers, wholesalers or pharmacists level runs through his own individual learning curve regarding the technical requirements and the internal processes that need to be adjusted. These long lead times, which take well over two years according to the experience gained in the context of the securpharm project, also speak for a stakeholder model analogue to the securpharm project. If the anti-counterfeiting directive comes into full effect in 2017, the verification systems would have to go online in 2014 due to the necessary lead times. To our knowledge, there are currently no projects in existence throughout Europe that are this advanced. 9
10 c) Direct financing of the databases by the stakeholders The database developed and operated by the stakeholders is financed exclusively by the stakeholders, even though the directive 2001/83/EC, article 54a, paragraph 2, e) states that the cost of the data storage and retrieval system needs to be borne by the holders of the manufacturing authorisation (i.e. by the pharmaceutical companies). This means that a competent authority may pre-finance the database system and refinance it by charging the pharmaceutical companies fees. Aside from budgetary problems, the competent authority needs to pass on the costs to the companies via a still to be developed cost and fee structure. This apportionment would be an unnecessary detour and consequently more complicated than the entire, fully functioning verification system financed, developed and tested by securpharm. d) Good tradition / experience with stakeholder models / self-governing models in Germany accessibility and supervision by competent authorities are a given In Germany, self-governing models and stakeholder models have been highly successful, not only in the health sector. The statutory health insurance system is being self-governed by the federal joint committee (Gemeinsamer Bundesausschuss). In the pharmaceutical market, the entire inventory management, logistics and billing of pharmaceuticals with the statutory health insurance companies has for decades been carried out on the basis of economic and legal information provided by the information centre for special medical products (Informationsstelle für Arzneispezialitäten IFA GmbH), which is supported by the pharmacists, pharmaceutical wholesalers and the pharmaceutical industry. In the past, the IFA has played a major role in implementing all legislation amendments, which makes this a stakeholder model. It is also expressly recognised as a central information service. Respective agreements with the central federal association of health insurers (Spitzenverband Bund der Krankenkassen) are in existence. Based on these positive experiences, the stakeholders have made an early decision in mid-2011 to take responsibility and to fund the securpharm project in order to develop, test and operate a system against counterfeit medicines, thereby contributing to the timely implementation of the anti-counterfeiting directive. Apparently, there are currently no other national stakeholder models in the European Union, and certainly no authority models for the implementation of the anti-counterfeiting directive, even though the directive has already been adopted in mid-2011 and the preparation and adequate testing of verification systems requires a considerable amount of time as can be seen in the case of secur- Pharm. Right from the start, securpharm and the individual stakeholders have always informed the German government and the European Commission on the development status of the project, exchanged opinions and experiences and taken into particular account the suggestions and ideas from the German federal ministry of health (Bundesministerium für Gesundheit). securpharm has always maintained that representatives of the federal ministry of health or downstream authorities should be represented on the board or management
11 bodies of securpharm. Such a participation gives the authorities access and gives them the opportunity to monitor the data storage and retrieval systems, as required by the directive. This participation now merely needs to be institutionalised. Moreover, both the legal obligation to label all packages correctly with the appropriate security features and the pharmacists duty to verify, as stated in 64 et seqq. AMG, are subject to supervision by the competent federal authorities. This supervision is in accordance with the guidelines and allows the authorities access to the data storage and retrieval system at any given time. Conclusion on II: The securpharm verification system allows the competent authorities to survey and access all data at any given time, i.e. this system is totally in line with the guidelines. 11
12 III. Cost-benefit-adequate data delivery and encoding of the security features in the data matrix code According to article 54a, paragraph 2, a), the Commission needs to determine in the delegated legal acts what the characteristics and technical specifications of the unique identifier are, because this allows the authenticity of medicinal products to be verified and individual packages to be identified. The costbenefit-ratio is to be taken into account here. At the stakeholder workshop on 6 December 2013, the EU Commission presented two options: a part-harmonisation and delivery / encoding of the data to fight counterfeit pharmaceuticals a complete harmonisation and delivery / encoding of additional data, also for other use. In the notification dated 31 January 2014, the Commission decided on the second option, i.e. the complete harmonisation. The Commission also decided that the symbology of the data matrix code is essential: The unique identifier will be placed in a 2D barcode. securpharm has also implemented the second option in its verification system. This means that securpharm encodes more data than absolutely necessary to combat counterfeit pharmaceuticals. In addition to the product master data that characterise the product type (cf. II b), the pharmaceutical company transmits the package specific packaging data, which is absolutely necessary for the verification, namely the randomised serial number the product number (in form of a PPN or NTIN that may contain a national billing number, see V. below) and the batch number and the expiry date.
13 IV. end to end -Verification These key data are encoded following the symbology of the data matrix code as per ISO/IEC These unique data elements are machine readable the world over, and each pharmaceutical package delivered can be verified at the pharmacy. Furthermore, the additional information regarding the batch number and the expiry date enables a quick and uncomplicated recall of the respective pharmaceutical product, should this be necessary. This information also enables an optimised stock holding and goods management within the pharmaceutical products trade. Conclusion on III: The securpharm verification system complies with the guidelines set out by the anti-counterfeiting directive and the delegated legal acts: securpharm encodes on the basis of the co-called complete harmonisation of data within the data matrix code. According to article 54a paragraph 2, d), the Commission is to determine the modalities for the verification of the security features in the delegated acts, which then need to be checked by the manufacturers, wholesalers, pharmacists and persons authorised to supply medicinal products to the public. When defining these modalities, the particular characteristics of the supply chains in the member states are to be considered as well as the need to ensure that the impact of the control measures remains proportionate to the position of the actors within the supply chains. In the workshop on 6 December 2013, the Commission presented two options: firstly, the systematic end-to-end verification, and secondly, the systematic verification at the delivery point and a risk-based verification by the wholesalers. In the notification dated 31 January 2014, the Commission opted for the end-to-end verification: Medicine authenticity will be guaranteed by an end-to-end verification system supplemented by risk-based verifications by wholesale distributors. securpharm has opted for the systematic endto-end verification. Here, the packages of the pharmaceutical products that are subject to verification are labelled with machine-readable security features in the packaging and manufacturing plant; the packages receive a randomised serial number which makes each one individually identifiable. The packaging data listed in III. are transmitted to the MAH database by the pharmaceutical company before the products are introduced to the market. There, the data is stored and used for verification by competent persons and authorities. The pharmacy software then points out to the pharmacist that he / she has the 13
14 V. duty to verify the product. To verify a package, the pharmacist needs to scan the data matrix code, which is marked with a PPN emblem, before handing out the product to the patient. Within milliseconds (current average response time with the securpharm system is 103 ms) the serial number and the product number are verified against the MAH database. If the status of the package is correct, the product may be handed out and will be registered as dispensed in the system. Exceptions, i.e. packages that cannot be verified, will be identified, withdrawn, evaluated by securpharm, and then all necessary measures will be initiated. This end-to-end approach fully complies with the demands of the directive as stated in article 54a, especially paragraph 2, d), according to which the authenticity of each delivered package of pharmaceutical product that requires authentication needs to be verified. The endto-end approach ensures that prescription drugs and pharmaceutical products that need to be verified can only be handed out in pharmacies if the package has previously been identified as authentic. In addition and within the framework of the risk-based approach, the wholesalers can initiate a check via the central pharmacies server if e.g. packages have been returned from pharmacies or have not been delivered directly from the producer. An additional verification by the patient is not necessary. Conclusion on IV: The securpharm verification system complies with the directive as set out by the Commission: the authenticity is checked using the end-to-end and risk-based approach. Market and system accessibility: PPN or NTIN as globally distinct product numbers verification system securpharm is in line with the directive and serves as blueprint for other EU member states In addition to the randomised serial number, a worldwide unique product number forms a central element of the verification, as a verification of individual medicine packages is impossible without a distinct product number. In Germany, the key element of this worldwide unique product number is the long-since used central pharmaceutical number (Pharmazentralnummer, PZN). As stated in 300 paragraph 3 article 1 no. 1 SGB V, this nationally standardised number for proprietary medicinal products entails the trade name, manufacturer, dosage form, strength of active ingredients and package size. From this eight-digit PZN, either the Pharmacy-Product-Number (PPN) or the National Trade Item Number (NTIN) is generated. The PPN is composed of the eightdigit PZN, a prefix for the Product Registration Agency Code (this PRA code ultimately indicates the country of origin) and two check digits. This ensures that the PPN is distinctive around the world. The NTIN is created likewise from the PZN, a country prefix and a check digit. To determine the PPN and the NTIN, securpharm has compiled extensive encoding rules that also allow for the numbers to be embedded in a data matrix code. While taking into account the respective licence terms, the pharmaceutical companies can decide between the two product num-
15 VI. bers and even switch between them, as the systems support both numbers and work conflict-free. Existing databases and software systems can algorithmically create a PZN from the PPN or NTIN or vice versa a PPN or NTIN from the PZN. Consequently, the already existing databases and applications can continue to work unchanged with the PZN. The interoperability with other numerical systems, e.g. GTIN (GS1 as issuing agency) or HIBC (EHIB- CC as issuing agency), is guaranteed due to the joint basis formed by the international ISO standards. The data content for batch number, expiry date and serial number is identical in both versions. Using the PPN or NTIN, the encoding rules developed by securpharm and used in the securpharm verification system generate globally unique product numbers and thereby ensure an open market while taking national demands into consideration. Due to the fact that the product numbers used by securpharm are globally unique, the overall system by securpharm could be a model on which to base other verification systems in other EU member states. Conclusion on V: securpharm is a verification system that complies with the anti-counterfeiting directive and therefore has the potential to be a blueprint for other EU member states. Technically and organisationally separate data storage and retrieval systems ensure the best possible data protection and data security As stated in article 54a paragraph 3 of the directive 2001/83/EC: when determining the delegated legal acts and deciding on how to implement, manage and make the data storage and retrieval system accessible, the Commission needs to consider the protection of personal data as determined by EU law, Ê Ê the legitimate interest to protect confidential information that is of a business nature, the property and confidentiality of the data produced by using the security features and the cost-effectiveness of the measures. Recital 11 of the anti-counterfeiting directive adds that the individual identifying feature and the corresponding data storage and retrieval system needs to have clearly defined and effective safety barriers to protect personal data and sensitive business information. securpharm is based on a concept of separate data systems. The pharmaceutical businesses upload their package-specific data onto the MAH database, which is run and financed by ACS PharmaProtect GmbH. Verification requests by pharmacists (and by wholesalers) are bundled and anonymised via the central 15
16 pharmacies server and passed on to the MAH database (for details about the verification process, see IV.). The concept, financing and implementation of the central pharmacies system has been undertaken by the data service ABDATA, a division of the advertising and sales company Werbe- und Vertriebsgesellschaft Deutscher Apotheker mbh. The securpharm system is a distributed system with separate data systems for pharmacists and pharmaceutical companies and is based on the principle that the (transaction) data for pharmaceutical products remain the property of the respective system operator. The system operators set up, maintain and finance their own data systems and retain all rights and duties over the data produced as a result of the security features. Due to the separate data storage and retrieval systems within the securpharm project, it is impossible for pharmaceutical companies to know, from which pharmacy a verification request comes. That is also why pharmaceutical companies cannot acquire information on purchase and sales numbers for individual pharmacies. Vice versa, the pharmacies cannot examine the data of the pharmaceutical companies. Third parties have no access at all to the data systems. Technical measures ensure the data separation and anonymity are upheld. Within the MAH database, the product data of the pharmaceutical companies remains the property of the respective business. ACS Pharma- Protect GmbH holds the data of the respective pharmaceutical company in trust. It provides a protected data space for every pharmaceutical company so that each pharmaceutical company also only has access to its own data. In this model, securpharm merely takes on the role of a supervisor. securpharm determines the rules of play for the entire system and reacts to any abnormalities that suggest a counterfeit product. These abnormalities or exceptions can have a technical cause, e.g. when the server is unavailable or the data matrix code is illegible. But also external attacks on the system or indeed counterfeit pharmaceutical products may be the cause. securpharm will identify these exceptions and conflicts and initiate the necessary measures to resolve the issue. Within the securpharm system, data protection and data security take the highest priority within the technical and organisational realisation of the verification process and are guaranteed by the database operators on all levels. All data is protected against attacks from frauds and hackers with the latest state-of-the-art security system. Conclusion on VI: With its distributed system with separate data storage and retrieval systems for pharmaceutical companies and pharmacies, the securpharm system provides the best possible data protection for personal data and sensitive business information.
17 VII. Fee model is cost-benefit-adequate and takes the properties of certain pharmaceutical products, especially of generics, into account According to the guiding principle as described in several clauses of the anti-counterfeiting directive, all rules, measures, options and stipulations of the delegated legal acts need to be checked for usefulness, costs and costeffectiveness by the Commission. All stipulations of the delegated legal acts need to have a reasonable cost-benefit ratio. The measures need to be cost-effective. As to the application area of the security features, recital 11 states that the properties of certain pharmaceutical products or categories of pharmaceutical products, e.g. generics, need to be taken into account adequately. In most member states of the European Union, generics make up a huge proportion of the overall number of pharmaceutical products sold. Take, for example, Germany: in 2012, a total of approx. 700 million packages of prescription drugs were sold. Roughly ¾ of these were generics, i.e. well over 500 million packages. Subject to the final determination of the scope of the Commission in the delegated legal acts, it is to be expected that the vast majority of the drug packages that need to be verified will be generics. Therefore, the manufacturers of generics will be most affected by the application and verification of the security features, also financially. In January 2014, bearing these facts in mind, ACS PharmaProtect introduced a fee model for the use of the ACS database and the securpharm verification system that takes the properties of the (German) pharmaceuticals market and especially the generics into account. The fee model of the ACS manufacturers database is based on three fee components, namely a one-off fee for installing the user on the database (initial set-up fee) a fixed monthly operating rate for providing the system and a basic support service (running fee) a fee per dataset (package) that is provided via the database system (dataset fee). The running fee and the dataset fee are scaled diminishingly, i.e. the greater the number of users and packages, the smaller the cost for the user. Pharmaceutical companies with small numbers of packages pay a higher price than businesses with greater numbers of packages, e.g. generics manufacturers. Based on this fee model and the practical experience gained thus far, ACS PharmaProtect GmbH estimates that the running costs of the ACS database would currently amount to under one cent per package, assuming approx. 600 million packages are sold per year (assumption is based on 700 million packages while taking potential exception lists, blacklist / whitelist into account). This is an average price: due to the diminishingly scaled running and dataset fees, the companies with a higher output of packages pay a correspondingly lower price per package. 17
18 VIII. According to calculations made by ACS, the fee model for operating the ACS database in Germany would cost the approx. 500 pharmaceutical companies a total of under five million Euros per year. These figures do not include the costs for the pharmacies system, the conflict resolving securpharm system, a possible EU Hub or the internal costs for the pharmaceutical businesses related to the serialisation and labelling of the packages. The current fee model is not fixed for all time. It will be necessary to adapt the fee model to the development of the project and to the experiences gained. Conclusion on VII: The ACS fee model is cost-benefit-adequate and, by introducing diminishingly scaled dataset fees, it takes into account the special circumstances of pharmaceutical companies that produce large numbers of packages (generics manufacturers). The average cost lies at well below one cent per package. While the costs for the pharmacies system and the conflict resolution system cannot be estimated accurately yet, it should be noted that the verification cost per package with the securpharm system lies well below the estimates and forecasts made by other organisations that predicted a cost per package of more than five cents. securpharm as blueprint for national verification systems can be integrated into a European shield against counterfeit pharmaceuticals The worldwide uniqueness of the product numbers used within the securpharm system (in form of a PPN or NTIN) and the globally usable encoding, verification and organisation regulations developed by securpharm make this system stand out. That is why securpharm represents a model for verification systems that could also be applied in other EU member states that want to / will have to implement the anti-counterfeiting directive. The country prefixes, contained in the PPN / NTIN product number, matches each package of pharmaceuticals that is up for verification to a particular PRA code / a certain country. Even pharmaceuticals used across national borders, so-called multi-country packs, and imported pharmaceuticals could be identified and verified Europe-wide via a central EU routing system. This not only makes securpharm a blueprint for verification systems in other EU member states, but also when using a central routing system a building block of a European shield against counterfeit pharmaceutical products.
19 IX. Afterword The experience gained from the securpharm project shows that such a complex system should only be set up, when various prerequisites regarding the (national) infrastructure are in place. The description above shows that only stakeholders have the necessary knowhow to set up such a system. Consequently, these stakeholders need to be sufficiently organised to be able to conduct the necessary business dealings. In addition, the stakeholders need to involve all trade levels (manufacturers, wholesalers and pharmacies) and be willing to cooperate. Lastly, the end-to-end verification i.e. using joint databases logically assumes that there is such a thing as a national item number for pharmaceutical products and that this number is used by all trade levels to identify said products. There is no other way of addressing the verification database by all trade levels. Ideally, this (necessarily unique*) number should also be the number that is used by the insurer/s to refund costs. Otherwise, the code would have to consist of 5 elements (item number and refund number, serial number, batch number, expiry date), which would mean redundant information, higher administrative costs and a greater number of errors. *This demand for a unique refund number results from drug safety aspects that come up in connection with dispensing pharmaceuticals to patients and from wanting to invoice the cost-bearer correctly. Item numbers from manufacturers generally do not meet this demand, as the numbers are not allocated according to universal guidelines and are not counterchecked. 19
20 securpharm e.v. Hamburger Allee Frankfurt am Main Registernummer VR Vereinsregister des Amtsgerichts Frankfurt am Main Tel. 069 / info@securpharm.de
IFA-Coding-System Transport Logistics Specification. Automatic identification of transport units in the pharmaceutical supply chain
IFA-Coding-System Transport Logistics Specification Automatic identification of transport units in the pharmaceutical supply chain Version: 1.00 Date of issue: December 2012 Table of Contents 1 Foreword
More informationDelegated Act on the Detailed Rules for a Unique Identifier for Medicinal Products for Human use, and its Verification
Delegated Act on the Detailed Rules for a Unique Identifier for Medicinal Products for Human use, and its Verification Concept Paper submitted for Public Consultation Response from securpharm e.v. 26 April
More informationA European Medicines Verification System
Ensuring patients have access to safe medicines A European Medicines Verification System Fighting counterfeit medicines to ensure patient safety in Europe Speaker: Ms. Monika Derecque-Pois Event: Scientific
More informationLindsey Gilpin, Chair, English Board, On behalf of the Royal Pharmaceutical Society
Response by the Royal Pharmaceutical Society to the European Commission s Concept paper on the Delegated Act on the detailed rules for a unique identifier tor medicinal products for human use, and its
More informationEuropean Medicines Verification System (EMVS) European Pack Coding Guidelines
European Medicines Verification System (EMVS) European Pack Coding Guidelines June 2013 Revision History V1.0 June 2008 Initial Release V1.1 June 2008 Amended some typographical errors, added extra detail
More informationTransport - track and trace with RFID and latest developments in barcoding
Transport - track and trace with RFID and latest developments in barcoding Thessaloniki, Dr. Knoth 21. April 2012 RFID- Technical data I RFID Radio-Frequency Identification I Uses non-contact identification
More informationPosition Paper (II) Healthcare Provider Advisory Council Implementation in hospitals hindered by bar code symbol issues
I. Introduction Towards the end of 2011, GS1 Healthcare established the Healthcare Provider Advisory Council (HPAC) to be the forum for sharing and discussing the practical realities of implementation
More informationWhite Paper Healthcare Supply Chain Traceability
Executive Summary This white paper focuses on Healthcare supply chain Traceability, from manufacture to patient, going beyond, for example, what is currently regulated by the US 21 CFR Part 820 and ISO
More informationGuidance for Manufacturers What is required to be ready to connect to the EMVS?
European Medicines Verification System: Guidance for Manufacturers What is required to be ready to connect to the EMVS? Version V 1.0 Authors: Christoph Krähenbühl, Marian Omtzigt, Stefan Artlich, Peter
More informationGS1 Healthcare Discussion paper on Mobile Applications and Services in Healthcare
Mobile Applications and Services In the last 20 years there has been a significant growth of mobile communication devices, such as mobile/cell phones, tablet computers and personal digital assistants (PDAs);
More informationUnique identification of pharmaceuticals in Austria
Unique identification of pharmaceuticals in Austria From the national Pharmazentralnummer to an international Global Trade Item Number Stefan Sabutsch GS1 Healthcare Conference Vienna 2009-03-19 Original
More informationEuropean Medicines Verification System (EMVS) Status March 2015
European Medicines Verification (EMVS) Status March 2015 Introduction Grant Courtney Previously a member of the EFPIA Serialisaiton & Coding Steering Team Member of GS1 Healthcare Leadership Team 20 Years
More informationNOT ALL CODES ARE CREATED EQUAL
NOT ALL CODES ARE CREATED EQUAL Why some serial numbers are better than others. Verify Brand 3033 Campus Drive, Minneapolis MN 55441 info@verifybrand.com (763) 235-1400 EXECUTIVE SUMMARY Serial numbers
More informationDrug Distribution Management Policy in Korea
Drug Distribution Management Policy in Korea Regarding introduction of Drug Serial Number System (Serialization) Ministry of Health and Welfare Drug Distribution Management Policy Overview Policy Objectives
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationLaser coding a technology of choice for the Pharmaceutical industry
Laser coding a technology of choice for the Pharmaceutical industry White Paper Introduction The year 2018 will see the implementation of new regulations in the fight against counterfeiting in the European
More informationGuidelines on operational functioning of colleges
EIOPA-BoS-14/146 EN Guidelines on operational functioning of colleges EIOPA Westhafen Tower, Westhafenplatz 1-60327 Frankfurt Germany - Tel. + 49 69-951119-20; Fax. + 49 69-951119-19; email: info@eiopa.europa.eu
More informationThe Business. for REDUCING DRUG ADMINISTRATION ERRORS USING 2D BARCODES
DnCirP+ A);. 1 39d~ - 71-\n- COMMERCIAL - IN - CONFIDENCE The Business Case for REDUCING DRUG ADMINISTRATION ERRORS Prepared by Mike Sim Chief Executive Officer Advias (Advanced Information Assurance Solutions
More informationTrack/Trace Solutions. for the Manufacturing Industry
Track/Trace Solutions for the Manufacturing Industry Today s manufacturers, regardless of what they produce, have no choice but to follow private sector and government required mandates. As examples, two
More informationCompilation of Community Procedures on Inspections and Exchange of Information
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 3 October 2014 EMA/572454/2014 Rev 17 Compliance and Inspection Compilation of Community
More information11 MEDICATION MANAGEMENT
1 11 MEDICATION MANAGEMENT OVERVIEW OF MEDICATION MANAGEMENT Depending on the size, structure and functions of the health facility, there may be a pharmacy with qualified pharmacists to dispense medication,
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
More informationEFPIA Good Practice Revision 1, October 2014
EFPIA Good Practice Revision 1, October 2014 Reducing Risk of Drug Products Shortages Introduction Authorities, industry and healthcare providers have a responsibility to ensure a modern and sustainable
More informationExplanatory notes VAT invoicing rules
Explanatory notes VAT invoicing rules (Council Directive 2010/45/EU) Why explanatory notes? Explanatory notes aim at providing a better understanding of legislation adopted at EU level and in this case
More informationEfficient Data Sharing in Healthcare
Efficient Data Sharing in Healthcare More and more efforts are underway in different countries on sharing data among doctors and hospitals in healthcare for achieving higher quality and efficiency of clinical
More informationPharmaceutical Distribution Security Alliance (PDSA)
Pharmaceutical Distribution Security Alliance (PDSA) Our Mission The Pharmaceutical Distribution Security Alliance's (PDSA) mission is to develop and help enact a federal policy proposal that enhances
More informationAN INTRODUCTION TO THE GLOBAL TRADE ITEM NUMBER (GTIN) TABLE OF CONTENTS
TABLE OF CONTENTS What Is a Global Trade Item Number?... 3 What Is a GTIN Used For?... 3 Key Attributes of the GTIN... 3 Business Benefits of Using GTINs... 3 How Is the GTIN Formed?... 4 Which GTIN Is
More informationMass Serialization and Traceability Implementation in the Pharma Industry. Mathieu Aman, Global Program Lead F. Hoffmann-La Roche Ltd, Switzerland
Mass Serialization and Traceability Implementation in the Pharma Industry Mathieu Aman, Global Program Lead F. Hoffmann-La Roche Ltd, Switzerland What drives the industry towards more traceability Strategic
More information20-21 May 2015, Lisbon, Portugal. Highlights. Speakers:
Speakers: Dr Afshin Hosseiny Chair of the ECA Expert Working Group on GDP, Tabriz Consulting Comply with the new EU GDP Guideline Dr Martin Egger Pharmaserv Dr Daniel Müller GMP/GDP Inspector All participants
More informationIBM Solution for Pharmaceutical Track & Trace
Secure and responsive supply chains IBM Solution for Pharmaceutical Track & Trace The underlying problem: Complexity in the pharmaceutical supply chain At its core, the pharmaceutical industry is about
More informationGeneral Protocol relating to the collaboration of the insurance supervisory authorities of the Member States of the European Union March 2008
CEIOPS-DOC-07/08 General Protocol relating to the collaboration of the insurance supervisory authorities of the Member States of the European Union March 2008 CEIOPS e.v. - Westhafenplatz 1 60327 Frankfurt
More informationSupport Guide for Codification of Medicines
Support Guide for Codification of Medicines To comply with RDC 54/2013 (Version 2) Support: Introduction... 3 Expected Benefits... 3 Applications... 4 Secondary Packaging:... 4 Identification: GTIN Codification:
More informationMessage 791 Communication from the Commission - SG(2012) D/50777 Directive 98/34/EC Notification: 2011/0188/D
Message 791 Communication from the Commission - SG(2012) D/50777 Directive 98/34/EC Notification: 2011/0188/D Reaction of the Commission to the response of a Member State notifying a draft regarding a
More informationThe Drug Supply Chain Security Act: Readiness and Implementation Update
The Drug Supply Chain Security Act: Readiness and Implementation Update Connie Jung, RPh, PhD U.S. Food and Drug Administration Center for Drug Evaluation and Research Office of Compliance Office of Drug
More informationWritten Contribution of the National Association of Statutory Health Insurance Funds of 16.11.2015
Written Contribution of the National Association of Statutory Health Insurance Funds of 16.11.2015 to the Public Consultation of the European Commission on Standards in the Digital : setting priorities
More informationThe certification process
TS004(COS)v01 The certification process for COSMOS standard Standard in force available on www.cosmos-standard.org or sent on request. 1 Contents I. When to apply... 3 II. The different steps in the certification
More informationGIRP views on the proposal for a revision of the European Good Distribution Practice Guidelines (GDP)
GIRP views on the proposal for a revision of the European Good Distribution Practice Guidelines (GDP) The Good Distribution Practice (GDP) Guidelines aim to ensure that a harmonised level of quality is
More informationDrug Supply Chain Security Act (Title II of the Drug Quality and Security Act) Overview and Implementation
Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act) Overview and Implementation Connie Jung, RPh, PhD U.S. Food and Drug Administration NACDS Total Store Expo August 24, 2014
More informationCompilation of Community Procedures on Inspections and Exchange of Information
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 27 June 2013 EMA/385898/2013 Rev 16 Compliance and Inspection Compilation of Community
More informationSpillemyndigheden s change management programme. Version 1.3.0 of 1 July 2012
Version 1.3.0 of 1 July 2012 Contents 1 Introduction... 3 1.1 Authority... 3 1.2 Objective... 3 1.3 Target audience... 3 1.4 Version... 3 1.5 Enquiries... 3 2. Framework for managing system changes...
More informationRECOMMENDATIONS by THE COMPANY LAW SLIM WORKING GROUP on THE SIMPLIFICATION OF THE FIRST AND SECOND COMPANY LAW DIRECTIVES
RECOMMENDATIONS by THE COMPANY LAW SLIM WORKING GROUP on THE SIMPLIFICATION OF THE FIRST AND SECOND COMPANY LAW DIRECTIVES Conclusions submitted by the Company Law Slim Working Group I. FIRST COUNCIL DIRECTIVE
More informationPharmaceutical Sector and
Introduction to the Pharmaceutical Sector and Rebate Contracts in Germany Dr. Frank Verheyen, Director WINEG Tim Steimle, Head of Pharmacy Department Hamburg, May 2010 General Facts about the pharmaceutical
More informationREDUCTION OF BUREAUCRATIC BARRIERS FOR SUCCESSFUL PV DEPLOYMENT IN THE EU KEY RECOMMENDATIONS
REDUCTION OF BUREAUCRATIC BARRIERS FOR SUCCESSFUL PV DEPLOYMENT IN THE EU KEY RECOMMENDATIONS September 2011 THE PV LEGAL PROJECT Many countries have already recognised the potential of solar energy and
More informationThe Role and Function of a Data Protection Officer in the European Commission s Proposed General Data Protection Regulation. Initial Discussion Paper
The Role and Function of a Data Protection Officer in the European Commission s Proposed General Data Protection Regulation 1. Introduction Initial Discussion Paper The data protection officer ( DPO )
More informationDraft guidance for registered pharmacies preparing unlicensed medicines
Draft guidance for registered pharmacies preparing unlicensed medicines January 2014 1 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacies
More informationThe successful introduction of a payment factory
Global Transaction Banking The successful introduction of a payment factory Implementing integration solutions based on best-practice components The purpose of this white paper The white papers published
More informationCoding rules for medicines requiring verification for the German market
Coding rules securpharm Coding rules for medicines requiring verification for the German market to protect against counterfeiting of medicinal products Coding of packaging using Data Matrix Code with the
More informationREGULATION. on the advertising of medicinal products. SECTION I Definitions, scope and general provisions.
REGULATION on the advertising of medicinal products. SECTION I Definitions, scope and general provisions. Article 1 Definitions. For the purposes of this Regulation, the following terms are used as defined
More informationSADC GUIDELINES ON IMPORT AND EXPORT PROCEDURES FOR PHARMACEUTICAL PRODUCTS
SADC GUIDELINES ON IMPORT AND EXPORT PROCEDURES FOR PHARMACEUTICAL PRODUCTS June 2006 1 INTRODUCTION Public health concerns demand that the manufacture of pharmaceutical products and their subsequent handling
More informationA Guide to Efficient MRO Procurement & Management White Paper
A Guide to Efficient MRO Procurement & Management White Paper Brammer 117554 WhitePaper_V5_SP.indd 1 19/04/2010 15:19 Executive summary The purchasing of spares for the daily maintenance, repair and overhaul
More informationInformation security controls. Briefing for clients on Experian information security controls
Information security controls Briefing for clients on Experian information security controls Introduction Security sits at the core of Experian s operations. The vast majority of modern organisations face
More informationEvolution of healthcare product coding and marking
n 3 May 2009 Evolution of healthcare product coding and marking Collaborators / authors This document is the result of the work from the partners of the healthcare product distribution chain: suppliers
More informationL 94/16 Official Journal of the European Union 30.3.2012
L 94/16 Official Journal of the European Union 30.3.2012 REGULATION (EU) No 259/2012 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 14 March 2012 amending Regulation (EC) No 648/2004 as regards the use
More informationSerialization, Traceability and e-pedigree
Serialization, Traceability and e-pedigree K.I.S.S. Keep It Simple & Sophisticated Written, compiled and edited by: Roy Cohen CTO of CryptoCodex Ltd Q@CryptoCodex.com 818-308-5414 Eddie Cohen CEO of 6DCP
More informationGRTGAZ NETWORK TRANSMISSION CONTRACT
Page 1 of 9 GRTGAZ NETWORK TRANSMISSION CONTRACT APPENDIX A3 STANDARD EVIDENCE AGREEMENT English translation for information. Disclaimer The present translation is not binding and is provided by GRTgaz
More informationReflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
1 2 3 5 August 2011 EMA/INS/GCP/600788/2011 Compliance and Inspection 4 5 6 7 Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials
More informationCompetentes en Medicamentos
VIII Encuentro de Autoridades Competentes en Medicamentos de los Países Iberoamericanos (EAMI) 12-14 de Mayo 2010 Madrid MARTIN TERBERGER Jefe de la Unidad de Productos Farmacéuticos Nuevas iniciativas
More informationGuideline on good pharmacovigilance practices (GVP)
9 April 2013 EMA/816573/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file (Rev 1) Draft of first version finalised by the Agency in collaboration
More informationCorporate Policy. Data Protection for Data of Customers & Partners.
Corporate Policy. Data Protection for Data of Customers & Partners. 02 Preamble Ladies and gentlemen, Dear employees, The electronic processing of virtually all sales procedures, globalization and growing
More information12 January 2011. Register of Interest Representatives Identification number in the register: 52646912360-95
Z E N T R A L E R K R E D I T A U S S C H U S S MITGLIEDER: BUNDESVERBAND DER DEUTSCHEN VOLKSBANKEN UND RAIFFEISENBANKEN E.V. BERLIN BUNDESVERBAND DEUTSCHER BANKEN E.V. BERLIN BUNDESVERBAND ÖFFENTLICHER
More informationCompliance issues for pharmaceutical companies in Germany
Financial institutions Energy Infrastructure, mining and commodities Transport Technology and innovation Life sciences and healthcare Compliance issues for pharmaceutical companies in Germany Ten things
More informationTR CMS 101:2011. Standard for Compliance Management Systems (CMS)
TR CMS 101:2011 Standard for Compliance Management Systems (CMS) of TÜV Rheinland, Cologne Total scope: 22 pages Contents Foreword....- 3-0 Introduction... - 5-1 Field of application... - 5-2 Aims of the
More informationOFFICIAL STATE GAZETTE. No. 269 Tuesday, November 8, 2011 Section 1 Page 116296 I. GENERAL PROVISIONS MINISTRY OF THE PRESIDENCY
OFFICIAL STATE GAZETTE No. 269 Tuesday, November 8, 2011 Section 1 Page 116296 I. GENERAL PROVISIONS MINISTRY OF THE PRESIDENCY Royal Decree 1495/2011, of 24 th October 2011, whereby the Law 37/2007, of
More informationQualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
More informationGeneral terms and conditions of business
General terms and conditions of business I. General information, offer and conclusion of contract 1. Consumers within the meaning of these general terms and conditions of business are natural persons with
More informationBasic principles of labelling and Electronic Data Interchange - Abridged version -
May 2008 Basic principles of labelling and Electronic Data Interchange - Abridged version - REWE Group wishes to implement the electronic exchange of master data and messages with as many partners as possible.
More informationEFPIA Principles for the Development of the EU Clinical Trials Portal and Database
Position Paper EFPIA Principles for the Development of the EU Clinical Trials Portal and Database Executive summary EFPIA sees the implementation of the Clinical Trials Regulation 1 as an opportunity to
More informationEUROPEAN COMMISSION Directorate General Internal Market and Services. CAPITAL AND COMPANIES Audit and Credit Rating Agencies
EUROPEAN COMMISSION Directorate General Internal Market and Services CAPITAL AND COMPANIES Audit and Credit Rating Agencies Brussels, 3 September 2014 Q&A - Implementation of the New Statutory Audit Framework
More informationCCBE comments on the proposal for a Directive of the European Parliament and of the Council on singlemember private limited liability companies
Conseil des barreaux européens Council of Bars and Law Societies of Europe Association internationale sans but lucratif Rue Joseph II, 40 /8 1000 Bruxelles T. : +32 (0)2 234 65 10 F. : +32 (0)2 234 65
More informationJUAN CARLOS I KING OF SPAIN
19814 LAW 37/2007 of 16 November 2007 on the re-use of public sector information JUAN CARLOS I KING OF SPAIN To all who see and understand this document. Be it known: That the Spanish Parliament has approved
More informationSpillemyndigheden s Certification Programme Change Management Programme
SCP.06.00.EN.1.0 Table of contents Table of contents... 2 1 Objectives of the change management programme... 3 1.1 Scope of this document... 3 1.2 Version... 3 2 Certification... 4 2.1 Certification frequency...
More informationMapping of outsourcing requirements
Mapping of outsourcing requirements Following comments received during the first round of consultation, CEBS and the Committee of European Securities Regulators (CESR) have worked closely together to ensure
More informationDSCSA Updates and Readiness Check: Requirements for Dispensers and other Trading Partners
DSCSA Updates and Readiness Check: Requirements for Dispensers and other Trading Partners U.S. Food and Drug Administration Center for Drug Evaluation and Research July 2015 Who is a Dispenser? DISPENSER.
More informationExample of a food company quality
Appendix A manual Example of a food company quality Contents Date: 13/03/95 RME-QLMN-OO Page 1 of 3 Section Title ISO 9001 reference 01 In trod uction 02 Purpose 03 Scope 04 Definitions 05 Management responsibility
More informationitac solutions for the medical industry Quality assurance of the highest standard FDA-compliant. Reliable. Productive.
Quality assurance of the highest standard FDA-compliant. Reliable. Productive. Market Requirements 1 Statutory regulations and stringent requirements laid down by the American regulatory authority, FDA
More informationNew Frontiers in the Quality of Medicines
New Frontiers in the Quality of Medicines Workshop Building a partnership for the investigation of counterfeit medicines Moderators: Dr Konstantin Keller Prof. Hendrick J. de Jong EDQM International Conference
More informationFinancial Services Guidance Note Outsourcing
Financial Services Guidance Note Issued: April 2005 Revised: August 2007 Table of Contents 1. Introduction... 3 1.1 Background... 3 1.2 Definitions... 3 2. Guiding Principles... 5 3. Key Risks of... 14
More informationWorking Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex
More informationInitial appraisal of a European Commission Impact Assessment
Initial appraisal of a European Commission Impact Assessment European Commission proposal for a Directive on the harmonisation of laws of the Member States to the making available on the market of radio
More informationHow To Use The Gs1 Databar Expanded
GS1 Standards GS1 DataBar in the meat industry Compact barcode with additional information for tracking and variable measured trade items GS1 Germany: Your dedicated partner for efficient business processes
More informationSANITARY AND PHYTOSANITARY MEASURES (SPS)
TEXTUAL PROPOSAL SANITARY AND PHYTOSANITARY MEASURES (SPS) Article 1 Scope and coverage This Chapter applies to all SPS measures that may, directly or indirectly, affect trade between the Parties. This
More informationEudraVigilance stakeholder change management plan
26 October 2015 EMA/797114/2014 Information Management Division Consultation of Project Maintenance Group 1 15 July 2015 Consultation of Eudravigilance Expert Working Group 23 September 2015 Consultation
More informationEnabling the secure use of RFID
Enabling the secure use of RFID BLACK ME/FOTOLIA.com Enhancing security of radio frequency identification to connect safely to the Internet of Things UHF radio frequency identification (RFID) promises
More informationSpillemyndigheden s Certification Programme Change Management Programme
SCP.06.00.EN.2.0 Table of contents Table of contents... 2 1 Introduction... 4 1.1 Spillemyndigheden s certification programme... 4 1.2 Objectives of the change management programme... 4 1.3 Scope of this
More informationLEGISLATION COMMITTEE OF THE CROATIAN PARLIAMENT
LEGISLATION COMMITTEE OF THE CROATIAN PARLIAMENT 2300 Pursuant to its authority from Article 59 of the Rules of Procedure of the Croatian Parliament, the Legislation Committee determined the revised text
More informationPosition of leading German business organisations
Bundesverband des Deutschen Groß- und Außenhandels March 2007 Position of leading German business organisations on Commission staff working document European Credit system for Vocational Education and
More informationHDE position on legislative package to regulate payment systems (MIF and PSD II)
[Transparency Register No.: 31200871765-41] HDE position on legislative package to regulate payment systems (MIF and PSD II) November 2013 I. Einleitung I. Introduction The German Retail Federation HDE
More informationQuality Assurance Agreement (QAA)
Quality Assurance Agreement (QAA) between W. GESSMANN GmbH Eppinger Str. 221, D-74211 Leingarten - hereafter "W. GESSMANN" - and Company Road, house number Postal code and city - hereafter called "Supplier"
More informationTrack and Trace in the Pharmaceutical Supply Chain
Track and Trace in the Pharmaceutical Supply Chain Edmund W. Schuster Visiting Operations Researcher Robin Koh Associate Director Auto-ID Labs Massachusetts Institute of Technology Cambridge, MA husetts
More informationCouncil of the European Union Brussels, 5 March 2015 (OR. en)
Council of the European Union Brussels, 5 March 2015 (OR. en) Interinstitutional File: 2013/0027 (COD) 6788/15 LIMITE TELECOM 59 DATAPROTECT 23 CYBER 13 MI 139 CSC 55 CODEC 279 NOTE From: Presidency To:
More informationSÉRIALISATION : UN CAS CONCRET DE CODIFICATION EN TURQUIE. Les Rencontres CIP/ACL 29 novembre 2012. Maison de l artisanat - Paris 8ème
SÉRIALISATION : UN CAS CONCRET DE CODIFICATION EN TURQUIE Maison de l artisanat - Paris 8ème LES RENCONTRES CIP/ACL 2012 14h00 14h30 Sérialisation : un cas concret de codification en Turquie o Doctor Saim
More informationIBM Solution for Pharmaceutical Track & Trace: Supply chain visibility drives overall performance
Secure and responsive supply chains IBM Solution for Pharmaceutical Track & Trace: Supply chain visibility drives overall performance Lack of product visibility in pharmaceutical supply chains At its core,
More informationTICSA. Telecommunications (Interception Capability and Security) Act 2013. Guidance for Network Operators. www.gcsb.govt.nz www.ncsc.govt.
TICSA Telecommunications (Interception Capability and Security) Act 2013 Guidance for Network Operators www.gcsb.govt.nz www.ncsc.govt.nz Contents Introduction...2 Overview of the Guidance...3 Focus of
More informationREGULATION (EEC) No 2309/93
REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use
More informationAdlib Hosting - Service Level Agreement
Adlib Hosting - Service Level Agreement June 2014 This service level agreement (SLA) applies to the Adlib Hosting services provided by Axiell ALM Netherlands BV, and includes the activities and facilities
More informationAccreditation of a Dispensing and Pharmacy Assistant programme, Boots UK
Accreditation of a Dispensing and Pharmacy Assistant programme, Boots UK Report of an accreditation event, 19 November 2010 Introduction The General Pharmaceutical Council (GPhC) is the statutory regulator
More informationDECISIONS ADOPTED JOINTLY BY THE EUROPEAN PARLIAMENT AND THE COUNCIL
L 218/82 EN Official Journal of the European Union 13.8.2008 DECISIONS ADOPTED JOINTLY BY THE EUROPEAN PARLIAMENT AND THE COUNCIL DECISION No 768/2008/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of
More informationISA Work Programme SECTION I
ISA Work Programme SECTION I TABLE OF CONTENTS INTRODUCTION...4 1. THE CONTEXT...4 1.1. The need for the ISA programme...4 1.2. The political context...4 2. THE ISA PROGRAMME...5 3. THE EUROPEAN INTEROPERABILITY
More informationPHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING This guideline supersedes guideline PHV 4 as of September 16 2008. 1. Introduction and general provisions 1.1 Purpose of the guideline The guideline
More informationQuestions & Answers. on e-cohesion Policy in European Territorial Cooperation Programmes. (Updated version, May 2013)
Questions & Answers on e-cohesion Policy in European Territorial Cooperation Programmes (Updated version, May 2013) This fact sheet was drafted jointly by INTERACT and European Commission (DG Regional
More information